KRIBIOLISA™ Reslizumab (CINQAIR™/CINQAERO™) ELISA
Enzyme Immunoassay for the quantitative determination of Reslizumab (CINQAIR/CINQAERO) in serum, plasma and cell culture supernatantnt
Receive your quote directly from the manufacturer.
Introduction:
Reslizumab is a humanized monoclonal antibody against human interleukin-5 (IL-5).Reslizumab binds specifically to IL-5, a key cytokine responsible for the differentiation, maturation, recruitment and activation of human eosinophils. By binding to human IL-5, it blocks its biological function; consequently survival and activity of eosinophils are reduced.
Intended Use:
The KRIBIOLISA™ Reslizumab (CINQAIR/CINQAERO) ELISA is used as an analytical tool for quantitative determination of Reslizumab (CINQAIR/CINQAERO) in serum, plasma and cell culture supernatant.
Principle:
The method employs the quantitative sandwich enzyme immunoassay technique. Antibodies to Reslizumab are pre-coated onto microwells. Samples and standards are pipetted into microwells and human Reslizumab present in the sample are bound by the capture antibody. Then, a HRP (horseradish peroxidase) conjugated anti-Reslizumab antibody is pipetted and incubated. After washing microwells in order to remove any non-specific binding, the ready to use substrate solution (TMB) is added to microwells and color develops proportionally to the amount of Reslizumab in the sample. Color development is then stopped by addition of stop solution. Absorbance is measured at 450 nm.
